BOTHELL, WA, November 8, 2025 — PharmaIN Corporation, a clinical-stage biopharmaceutical company, today unveiled promising early results from the single-ascending dose phase of its Phase 1 trial of PHIN-214, a potential outpatient therapy for managing portal hypertension and its complications in patients with cirrhosis. Douglas Simonetto, M.D., Mayo Clinic College of Medicine and Science, Rochester, MN presented the findings at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting® on November 8, 2025, in Washington, D.C.

“We are pleased to announce the successful completion of the single-ascending dose study with PHIN-214,” said Dr. Simonetto. “PHIN-214, a partial V1a receptor agonist, offers a once-daily subcutaneous option that may enable longer-term self-administration outside of clinical settings. The initial results are encouraging, showing increases in mean arterial pressure and estimated glomerular filtration rate (eGFR), along with a low incidence of adverse events. We are excited to advance to the multi-ascending dose phase, which is already underway.”

Key findings presented at the Liver Meeting® include:

• The single-ascending dose phase of the study, in which 15 subjects received treatment across eight dose levels, has been successfully completed.
• PHIN-214 was generally well tolerated, exhibiting a safety profile consistent with on-target V1a receptor engagement.
• Pharmacokinetic data support once daily dosing with minimal predicted drug accumulation.
• PHIN-214 treatment improved renal function, with a median maximum 40.3% increase in eGFR observed during the first 12 hours after PHIN-214 administration and sustained at 24 hours in most participants (median increase of 16%).
• PHIN-214 treatment resulted in a median Mean Arterial Pressure (MAP) increase of 3.2mmHg over the first 12 hours, with a statistically significant elevation observed at 7 hours following PHIN-214 administration.
• These emerging findings support the continued development of PHIN-214 as a self-administered, subcutaneous therapy for managing complications of portal hypertension in patients with decompensated cirrhosis.

Poster Details:

Abstract Title: PHASE 1, SINGLE-ASCENDING DOSE RESULTS FROM THE PHIN-001 STUDY OF PHIN-214 IN COMPENSATED AND DECOMPENSATED PATIENTS WITH CIRRHOSIS

Authors: Douglas A. Simonetto¹, Naim Alkhouri², Ethan Weinberg³, Christina C. Lindenmeyer⁴, Gary Reiss⁵, Eric Lawitz⁶

¹Mayo Clinic College of Medicine and Science, Rochester,²Arizona Liver Health,³University of Pennsylvania,⁴Cleveland Clinic Foundation,⁵Tandem Clinical Research,⁶Texas Liver Institute, University of Texas Health San Antonio

Abstract Number: 2404

Poster is available on the Publication page under Pipeline of PharmaIN website.

About PHIN-214:

PHIN-214 is an optimized vasopressor therapy designed to target a clinically validated mechanism of action in portal hypertension. Presented as a convenient subcutaneous injection, PHIN-214 offers a potentially safer and more practical treatment option for management of complications associated with portal hypertension in patients with advanced cirrhosis.   

PharmaIN is currently enrolling patients for the multiple ascending dose part of its Phase 1 clinical trial evaluating PHIN-214 (NCT05490888).

About PharmaIN:

PharmaIN Corporation, based in Bothell, WA, is a clinical-stage biopharmaceutical company pioneering first- and best-in-class subcutaneous therapies through thoughtful peptide engineering. By leveraging its expertise in target-specific biology, peptide drug design, and innovative drug delivery, PharmaIN is focused on developing novel treatments for patients with advanced cirrhosis and cancer. Visit our website at www.pharmain.com.

FOR FURTHER INFORMATION, PLEASE CONTACT: BD@pharmain.com